The current race to develop vaccines against the Bundibugyo Ebola strain in the DRC and Uganda extends beyond the immediate 1,100+ suspected cases and highlights systemic underinvestment in non-Zaire strains, a pattern seen across 17 prior DRC outbreaks. While the MedicalXpress coverage notes the rVSV platform's promise and Geisbert's 2013 monkey data showing strong protection, it underplays that this remains preclinical evidence from small-sample animal models lacking human RCT validation or peer review on efficacy endpoints. Synthesizing this with the 2015 Ebola Ça Suffit! ring vaccination trial (Lancet, cluster-randomized, n=7,651, high-quality RCT but Zaire-specific with no industry conflicts) and CEPI's broader portfolio reports reveals missed opportunities: pharma disinterest stalled Bundibugyo candidates for a decade despite known cross-strain risks. Observational data from prior outbreaks further shows community trust barriers in conflict zones exacerbate trial delays, a gap mainstream reporting often ignores. Gavi's $50M pledge signals risk-sharing but conflicts with historical underfunding patterns, where mRNA platforms like Moderna's (building on COVID observational studies, large n but observational bias) could accelerate yet face manufacturing inequities in low-resource settings. This connects to urgent health security lapses, as active outbreaks expose how neglecting rare strains invites wider spillover.